NanoSyrinx Ltd.

https://www.nanosyrinx.com

NanoSyrinx is an emerging biotechnology company developing a novel cell engineering system for targeted delivery of therapeutic proteins and peptides direct to the cytosol. NanoSyrinx was co-founded in 2020 by Dr. Healey, Dr. Waterfield and Dr. Hapeshi to commercialise the team’s research at the University of Warwick’s Medical School. Dr Stephen Taylor, previously an SVP at Fujifilm Diosynth, has joined the company as Chairman, along with Dr. Jane Dancer, NED, whose past roles include CBO at F-Star and Director of Business Development at MedImmune. *

	Start	2018-09-29 established
	Industry	synthetic biotechnology
	Industry 2	drug delivery technology for biologics
	Person	Healey, Joseph R.J. (Joe) (NanoSyrinx 202012 CEO + Co-Founder)

	Region	Coventry, Warwickshire
	Country	United Kingdom (GB)
	Street	Unit 27D University of Warwick Science Park, The Venture Centre
	City	CV4 7EZ Coventry
		Address record changed: 2020-12-12

Basic data	Employees	n. a.

		* Document for »About Section«: NanoSyrinx Ltd.. (7/19/21). "Press Release: NanoSyrinx Raises £6.2m to Develop Its Synthetic Biology Platform for Targeted Intracellular Engineering". Coventry.

		Record changed: 2023-07-10

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

More documents for NanoSyrinx Ltd.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)